Cell culturing technology Cellink has bought University of Freiburg's single-cell dispensing spinout Cytena for almost $34m.

The orphan disease drug developer's latest round was led by Novo while Asahi Kasei and Chiesi Ventures also participated, taking its overall funding to $46m.

Mission Bay Capital has backed a series B round for orphan diseases drug developer Glycomine, which also attracted Novo, Asahi Kasei Pharma and Chiesi.

BlueDot, a disease containment technology spinout set up by St Michael’s Hospital and Mars Innovation, has secured series A capital.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Hillrom is paying $130m to snap up Johnson & Johnson-backed respiratory therapy system developer Breathe, which had raised at least $62m in funding.

UVC Partners has backed a $13.5m round that came four years after the diagnostic technology spinout of LMU secured a series B featuring UnternehmerTUM.

Celgene and Astellas Venture Management each supplied a portion of the round to bring the Caltech-founded cancer drug developer's lifetime funding to $92m.

OUP, Celgene and Astellas Venture Management all supplied a portion of the funding to bring the Caltech-founded cancer drug developer's lifetime funding to $92m.

Robert Bosch Venture Capital has returned for a $13.5m round that came four years after the diagnostic technology developer's series B.